TAMPA, Fla.--(BUSINESS WIRE)--Marc Peden, MD of Retina Associates of Florida, PA will present “Long-Term Visual Outcomes in Patients Receiving Continuous, Fixed-Interval Dosing of Anti-VEGF Therapy for Wet Age-Related Macular Degeneration” at the 2014 American Society of Retinal Specialists (ASRS) annual conference.
Anti-vascular endothelial growth factor (VEGF) inhibitors, including Lucentis, Avastin and Eylea, have proven to reduce vision loss in patients with wet, age-related macular degeneration (AMD), even improving vision in some cases. The question Retina Associates of Florida researched is how often treatment should occur.
“We’ve always felt that our patients with wet AMD are best treated with fixed, regular injections of anti-VEGF drugs, and these results confirmed our beliefs,” Dr. Peden said. “We compared outcomes data from our patients to data from other studies with patients receiving ‘as needed treatment,’ that is treatment only the disease is present.’”
The analysis concluded that providing anti-VEGF therapy every four to eight weeks resulted in favorable long-term sight preservation in patients with wet AMD out to seven years. “With this method of treatment we found that patients are about half as likely to go blind and almost twice as likely to maintain driving vision compared to as needed treatment,” Dr. Peden said.
Dr. Peden will share these results on Aug. 9 at the 2014 ASRS annual conference being held in San Diego, Calif., from Aug. 9 through 13. ASRS provides a platform for sharing research and information among retinal specialists. Its more than 2,400 members represent the United States and more than 55 other countries.
About Retina Associates of Florida
Retina Associates is a state-of-the art diagnostic and treatment center as well as a leading clinical research center for macular degeneration and other retinal diseases. Its physicians are Mark Hammer, MD, Ivan Suñer, MD and Marc Peden, MD who are consistently voted "Best Doctors in America." Retina Associates of Florida has pioneered several procedures and conducted clinical trials on ophthalmic medications, including the breakthrough macular degeneration drugs, Lucentis and Macugen. The main clinic is located at 602 South MacDill Ave. in Tampa and can be reached at 813-875-6373. Additional information is available at www.tamparetina.com.